|
WO2021074196A1
|
|
Thienopyrimidones as trpa1 inhibitors
|
|
WO2021074198A1
|
|
Novel tetrazoles
|
|
WO2021074197A1
|
|
Thienopyrimidones as trpa1 inhibitors
|
|
WO2021069353A1
|
|
Bioreactor or fermenter for the culturing of cells or microorganisms in suspension in industrial scale
|
|
US2021107983A1
|
|
Multi-specific binding proteins for cancer treatment
|
|
WO2021058713A1
|
|
Concentrated perfusion medium
|
|
US2021087282A1
|
|
Anti-nrp1a antibodies and their uses for treating eye or ocular diseases
|
|
IL277493D0
|
|
Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
|
|
US2021070852A1
|
|
Anti-IL-23p19 Antibody Formulations
|
|
US2021061761A1
|
|
Modulators of complex i
|
|
WO2021013833A1
|
|
N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (atx) modulators for the treatment of inflammatory airway or fibrotic diseases
|
|
US2021024492A1
|
|
Novel pyridazines
|
|
US2021024495A1
|
|
Novel pyridazines
|
|
WO2020264065A1
|
|
Anti-angpt2 antibodies
|
|
WO2020260252A1
|
|
New macrocyclic compounds and derivatives as egfr inhibitors
|
|
WO2020254644A1
|
|
Novel mechanism to control rna virus replication and gene expression
|
|
WO2020254451A1
|
|
Anticancer combination therapy
|
|
WO2020245137A1
|
|
Imidazopyrazine derivatives and the use thereof as medicament
|
|
WO2020245136A1
|
|
Purine derivatives, as nr2b negative modulators and the use thereof as medicament, in particular for treating depressive disorders
|
|
WO2020225400A1
|
|
Anti-sema3a antibodies and their uses for treating eye or ocular diseases
|
